Advanced Cell Diagnostics Appoints Tom Olenic as Chief Commercial Officer

HAYWARD, CALIFORNIA, December 2, 2014: Advanced Cell Diagnostics, Inc. (ACD), a world leader in the field of in situ nucleic acid detection for life science research and clinical diagnostics, today announced the appointment of Tom Olenic to its executive leadership team as Chief Commercial Officer.

 

Mr. Olenic has more than 25 years’ commercial and executive management experience in the biotechnology industry. Prior to joining ACD, Tom was General Manager of the Sequencing Organization and Senior VP of Commercial Operations of the Forensic Organization at IntegenX, Inc., where he implemented an aggressive global commercial strategy that achieved rapid revenue growth. He has also held commercial and senior management roles in companies ranging from startups to public corporations including Bios Corp., PerSeptive Bioscience, Millipore, Molecular Devices (a Danaher Company) and FreeSlate. At Molecular Devices, Tom held successful commercial leadership positions with increasing responsibilities, ending as the General Manager of an organization that grew from $10 million to over $200 million in annual revenue.

 

“ACD and its RNAscope technology have already established a great reputation in life science research. I’m so excited to build on the early success and help scale up the commercialization to the next level.” said Mr. Olenic.

 

“ACD's RNAscope has become indispensable for many researchers at the cutting edge to address the challenges of tumor heterogeneity and tumor microenvironment.” said Dr. Yuling Luo, Chief Executive Officer at ACD. “Tom has a proven track record of success in commercialization from early to major markets. He is a perfect fit for ACD to make RNAscope the assay of choice for the mainstream researchers and pathologists in this genomic era,” Dr. Luo continued.

 

For further information, please visit www.acdbio.com.

 

 

About Advanced Cell Diagnostics

 

Advanced Cell Diagnostics, Inc. (ACD) is a leader in molecular pathology, developing cell and tissue‐based diagnostic tests for precision medicine. The company’s products and services are based on its proprietary RNAscope^® technology, the first multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single‐molecule sensitivity. RNAscope assays are currently used by over a thousand customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases.  ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop proprietary diagnostic tests in cancer management.

 

Learn more about ACD and RNAscope technology at www.acdbio.com.